Patients with inflammatory bowel disease who received home infusions of Remicade had higher rates of nonadherence and discontinuation of the drug, according to study results.

K.T. Park, MD, MS, of Stanford Health Care, and colleagues wrote that home infusions of Remicade (infliximab, Janssen) are becoming more common because of lower costs and payer mandates.

“However, in-home service agencies are often not affiliated with the treating physician’s health system, and there is an absence of regulations regarding infusion practices,” they wrote. “Recent position statements

Full Article: